Literature DB >> 15306584

IgA antibodies of coeliac disease patients recognise a dominant T cell epitope of A-gliadin.

E A L Bateman1, B L Ferry, A Hall, S A Misbah, R Anderson, P Kelleher.   

Abstract

BACKGROUND: In coeliac disease (CD) patients, the dominant DQ2-Alpha-I-gliadin peptide recognised by CD4 T cells is contained within peptide sequence 57-73 (p57-73) of Alpha-gliadin. This peptide sequence is also located within a 33-mer protease resistant gliadin fragment and therefore is likely to play an important role in the pathogenesis of CD. AIMS: Our aim was to determine whether a B cell epitope was present within the immunodominant T cell epitope of Alpha-gliadin and, if so, to elucidate its sequence and determine the importance of deamidation and/or modification of the amino acid at position 65 for IgA binding. PATIENTS AND METHODS: A cohort of CD patients, disease controls, and healthy individuals were examined. Serum IgA antibodies to the native and modified p57-73 fragment of Alpha-gliadin were analysed using enzyme linked immunosorbent assays. Peptide scanning experiments were further used to elucidate the B cell epitope. RESULTS AND
CONCLUSION: IgA antibodies to p57-73 were found in 29/72 (40.2%) endomysial antibody positive patients, all of whom had CD. The peptide antibody appeared to be present when patients were on a diet containing gluten and declined on a gluten free diet. The p57-73 antibody was very specific for CD (98%) and had a sensitivity of 56%. The amino acid at position 65 was not important for IgA binding but was crucial for T cell recognition of p57-73. Pentapeptide PXPQP emerges as a potentially strong candidate for the IgA binding motif in this region of Alpha-gliadin. This study shows that a significant proportion of newly diagnosed CD patients have an antibody response to the immunodominant T cell epitope.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15306584      PMCID: PMC1774203          DOI: 10.1136/gut.2003.032755

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  19 in total

1.  Intranasal administration of one alpha gliadin can downregulate the immune response to whole gliadin in mice.

Authors:  F Maurano; R A Siciliano; B De Giulio; D Luongo; M F Mazzeo; R Troncone; S Auricchio; M Rossi
Journal:  Scand J Immunol       Date:  2001-03       Impact factor: 3.487

2.  In vivo antigen challenge in celiac disease identifies a single transglutaminase-modified peptide as the dominant A-gliadin T-cell epitope.

Authors:  R P Anderson; P Degano; A J Godkin; D P Jewell; A V Hill
Journal:  Nat Med       Date:  2000-03       Impact factor: 53.440

3.  Glutenin is involved in the gluten-driven mucosal T cell response.

Authors:  Y van de Wal; Y M Kooy; P van Veelen; W Vader; S A August; J W Drijfhout; S A Peña; F Koning
Journal:  Eur J Immunol       Date:  1999-10       Impact factor: 5.532

Review 4.  The widening spectrum of celiac disease.

Authors:  J A Murray
Journal:  Am J Clin Nutr       Date:  1999-03       Impact factor: 7.045

5.  Coeliac disease--a future for peptide therapy?

Authors:  A M Mowat
Journal:  Lancet       Date:  2000-07-22       Impact factor: 79.321

6.  B cell epitopes of gliadin.

Authors:  A A Osman; T Günnel; A Dietl; H H Uhlig; M Amin; B Fleckenstein; T Richter; T Mothes
Journal:  Clin Exp Immunol       Date:  2000-08       Impact factor: 4.330

7.  Biomedicine. Gluten and the gut-lessons for immune regulation.

Authors:  Detlef Schuppan; Eckhart G Hahn
Journal:  Science       Date:  2002-09-27       Impact factor: 47.728

8.  Celiac disease: antibody recognition against native and selectively deamidated gliadin peptides.

Authors:  M Aleanzi; A M Demonte; C Esper; S Garcilazo; M Waggener
Journal:  Clin Chem       Date:  2001-11       Impact factor: 8.327

Review 9.  Current approaches to diagnosis and treatment of celiac disease: an evolving spectrum.

Authors:  A Fasano; C Catassi
Journal:  Gastroenterology       Date:  2001-02       Impact factor: 22.682

10.  Structural basis for gluten intolerance in celiac sprue.

Authors:  Lu Shan; Øyvind Molberg; Isabelle Parrot; Felix Hausch; Ferda Filiz; Gary M Gray; Ludvig M Sollid; Chaitan Khosla
Journal:  Science       Date:  2002-09-27       Impact factor: 47.728

View more
  5 in total

Review 1.  Immunogenetic Pathogenesis of Celiac Disease and Non-celiac Gluten Sensitivity.

Authors:  Celia Escudero-Hernández; Amado Salvador Peña; David Bernardo
Journal:  Curr Gastroenterol Rep       Date:  2016-07

2.  Restricted VH/VL usage and limited mutations in gluten-specific IgA of coeliac disease lesion plasma cells.

Authors:  Øyvind Steinsbø; Carole J Henry Dunand; Min Huang; Luka Mesin; Marlene Salgado-Ferrer; Knut E A Lundin; Jørgen Jahnsen; Patrick C Wilson; Ludvig M Sollid
Journal:  Nat Commun       Date:  2014-06-09       Impact factor: 14.919

3.  Identification of Isopeptides Between Human Tissue Transglutaminase and Wheat, Rye, and Barley Gluten Peptides.

Authors:  Barbara Lexhaller; Christina Ludwig; Katharina Anne Scherf
Journal:  Sci Rep       Date:  2020-05-04       Impact factor: 4.379

4.  Secretory IgA mediates retrotranscytosis of intact gliadin peptides via the transferrin receptor in celiac disease.

Authors:  Tamara Matysiak-Budnik; Ivan Cruz Moura; Michelle Arcos-Fajardo; Corinne Lebreton; Sandrine Ménard; Céline Candalh; Karima Ben-Khalifa; Christophe Dugave; Houda Tamouza; Guillaume van Niel; Yoram Bouhnik; Dominique Lamarque; Stanislas Chaussade; Georgia Malamut; Christophe Cellier; Nadine Cerf-Bensussan; Renato C Monteiro; Martine Heyman
Journal:  J Exp Med       Date:  2007-12-31       Impact factor: 14.307

5.  Gluten-specific antibodies of celiac disease gut plasma cells recognize long proteolytic fragments that typically harbor T-cell epitopes.

Authors:  Siri Dørum; Øyvind Steinsbø; Elin Bergseng; Magnus Ø Arntzen; Gustavo A de Souza; Ludvig M Sollid
Journal:  Sci Rep       Date:  2016-05-05       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.